Aibotics, Inc. income statement AIBT

In fiscal 2025, which ended Dec 31, 2025, Aibotics, Inc. reported revenue of $2,183. It recorded a net loss of $2.2 million. The operating loss came to $1.8 million, an operating margin of -84501.7%. Over the twelve months ended Jun 30, 2026, revenue was $0 and the net loss was $2.1 million.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
Revenue
0
0
—
—
—
—
Gross profit
0
0
—
—
—
—
Selling, general and administrative
2
-2.6%
2
+13.0%
2
+165.1%
1
-64.5%
2
-65.2%
5
Operating expenses
2
2
—
—
—
—
Operating income
-2
+2.5%
-2
-12.8%
-2
-165.1%
-1
+64.5%
-2
+65.2%
-5
Other income (expense)
-0
-42.4%
-0
-73.8%
-0
+62.2%
-1
+35.5%
-1
-477.4%
-0
Pretax income
-2
-3.2%
-2
-19.9%
-2
-56.5%
-1
+54.8%
-3
+49.2%
-5
Income tax
0
0
0
0
0
0
Net income
-2
-3.2%
-2
-19.9%
-2
-56.5%
-1
+54.8%
-3
+49.2%
-5
Net income to common
—
-0
—
—
—
—
Other measures
Depreciation and amortization
0
0
-100.0%
0
-50.1%
0
-0.3%
0
+302.0%
0
EBITDA
-2
+2.5%
-2
-12.9%
-2
-165.4%
-1
+64.5%
-2
+65.2%
-5
Interest coverage
-8.62x
-8.13x
-7.66x
-1.09x
-2.01x
-34.86x
Margins
Gross margin
—
100.00%
—
—
—
—
Operating margin
—
-84,501.74%
—
—
—
—
Pretax margin
—
-101,500.27%
—
—
—
—
Profit margin
—
-101,500.27%
—
—
—
—
EBITDA margin
—
-84,501.74%
—
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Medicinal Chemicals & Botanical Products (SIC 2833)
Listed as
AIBT (OTC)
Fiscal year ends
December 31
Incorporated in
NV
Headquarters
Heyburn, ID
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1763329
Former names
Mycotopia Therapies, Inc. (until Dec 17, 2024); 20/20 Global, Inc. (until May 19, 2021)

Other Medicinal Chemicals & Botanical Products companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.